Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines ; volume:10 ; number:1 ; day:1 ; month:11 ; year:2024 ; pages:1-5 ; date:12.2024
Cardio-Oncology ; 10, Heft 1 (1.11.2024), 1-5, 12.2024
- Creator
-
Onoue, Takeshi
Matthews, Andrew H.
Vakilpour, Azin
Kang, Yu
Lefebvre, Bénédicte
Smith, Amanda M.
McCurdy, Shannon R.
Fradley, Michael G.
Carver, Joseph
Chittams, Jesse
Scherrer-Crosbie, Marielle
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40959-024-00275-5
- URN
-
urn:nbn:de:101:1-2501212104191.634275165168
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Onoue, Takeshi
- Matthews, Andrew H.
- Vakilpour, Azin
- Kang, Yu
- Lefebvre, Bénédicte
- Smith, Amanda M.
- McCurdy, Shannon R.
- Fradley, Michael G.
- Carver, Joseph
- Chittams, Jesse
- Scherrer-Crosbie, Marielle
- SpringerLink (Online service)
Other Objects (12)
Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia
Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia
Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations
Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia
Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax
CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis
Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia
Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia
Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations
Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia
Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax
CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis
Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia
Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia
Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations
Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia
Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax
CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab